Cargando…
Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years
BACKGROUND: How anti-mitochondrial antibody (AMA) and liver biochemistry levels change in primary biliary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) remains unclear. METHODS: A 28-year cohort of 157 PBC patients was conducted. Patients with alkaline phosphatase (Alk-p) level...
Autores principales: | Chang, Ming-Ling, Chen, Wei-Ting, Chan, Tien-Ming, Lin, Cheng-Yu, Chang, Ming-Yu, Chen, Shiang-Chi, Chien, Rong-Nan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160714/ https://www.ncbi.nlm.nih.gov/pubmed/35663951 http://dx.doi.org/10.3389/fimmu.2022.869018 |
Ejemplares similares
-
Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021) -
External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018) -
Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022) -
Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019) -
The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study
por: Lin, Cheng-Yu, et al.
Publicado: (2019)